Ehlers-Danlos syndrome can be a devastating disease in patients who are severely affected — a situation made worse by the current scarcity of treatment options.
“The life expectancy for those patients is really diminished, perhaps around 50 to 51 years of age, depending on what form they have,” David R. Deyle, MD, medical geneticist at the Mayo Clinic in Rochester, Minnesota, told Healio. “For those who are severely affected, it can be really bad.”
The FDA in December granted orphan drug designation to enzastaurin (AR101, Aytu Biopharma) for the treatment of